
    
      A dose-escalation and dose-expansion study of MEDI4736 (a monoclonal antibody that targets
      programmed cell death-1 ligand 1 [PD-L1]) to evaluate the safety, tolerability, PK, IM, and
      antitumor activity of MEDI4736 as monotherapy or in combination with Tremelimumab with or
      without Azacitidine in adult patients with myelodysplastic syndrome.
    
  